Ketamine vs. TMS: Choosing the Right Depression Path

A Mainstream Spotlight on Two Powerful Depression Treatments

A new explainer from Medical Daily, published May 14, 2026, walks readers through the decision process for two of the most discussed interventions for treatment-resistant depression (TRD): transcranial magnetic stimulation (TMS) and ketamine therapy. The piece outlines the clinical benchmarks — typically two or more failed antidepressant trials — that qualify patients for these advanced options, and describes what each treatment involves in terms of mechanism, timeline, and realistic expectations.

For the millions of Americans whose depression has not responded to standard medications and therapy, coverage like this marks a genuine shift: the conversation around TRD is becoming more accessible and far less stigmatized. Both TMS and ketamine are increasingly recognized not as last resorts, but as evidence-based tools that deserve a place earlier in the care conversation than they have historically occupied.

Ketamine and TMS Work Differently — And That Distinction Is Clinically Important

One of the most useful things coverage like Medical Daily’s does is clarify that ketamine and TMS are not interchangeable options. They work through entirely different mechanisms, and those differences have real consequences for which patients are likely to respond, how quickly relief arrives, and what the treatment experience actually involves.

TMS uses targeted magnetic pulses to stimulate underactive neural circuits associated with mood regulation. It is non-invasive, requires no sedation, and is typically administered daily over four to six weeks at an outpatient clinic. Insurance coverage for TMS has improved considerably, making it a realistic first-line option for many TRD patients. The trade-off: the time commitment is significant, and clinical response can take several weeks to emerge.

Ketamine — whether delivered as an intravenous infusion, intramuscular injection, or through FDA-approved intranasal esketamine (Spravato) — operates via a completely different pathway, acting on NMDA glutamate receptors in ways that appear to rapidly reset dysfunctional neural connections. Its most striking clinical feature is speed: many patients report meaningful relief within hours to days of a first infusion. That rapid onset makes ketamine particularly relevant for patients with acute suicidal ideation or those who cannot afford the longer ramp-up time of other interventions.

For patients weighing these options through a telehealth provider, the real question is not which treatment wins on paper — it is which is the right fit for their specific clinical history, schedule, geography, and out-of-pocket budget. That determination requires individualized guidance from a qualified clinician, not a standardized intake algorithm.

Five Questions to Ask Before Starting Telehealth Ketamine Treatment

As mainstream outlets continue to demystify ketamine for TRD, more patients are turning to telehealth platforms as their entry point. The convenience is real — but the differences between providers are equally real. Here is what the clinical evidence, and coverage like Medical Daily’s, suggests patients should examine before committing to an online program.

What modality are you actually receiving? Most telehealth ketamine programs in 2026 deliver treatment via oral ketamine — sublingual troches or lozenges dispensed through a compounding pharmacy — rather than IV infusion. Oral ketamine has lower bioavailability than IV but can still produce meaningful antidepressant effects with appropriate dosing and integration support. Understanding exactly what you are receiving, and why that form was chosen for you specifically, is a reasonable first question.

How rigorous is the screening process? Responsible ketamine providers do not accept every applicant. A thorough intake — including psychiatric history review, medical screening for contraindications, and a live video consultation with a licensed clinician — is a green flag, not a bureaucratic obstacle. If a platform offers rapid approval with minimal clinical contact, that warrants caution before proceeding.

What does follow-up care look like? The growing body of evidence on ketamine’s long-term effectiveness increasingly points to integration — psychotherapy, lifestyle support, and maintenance dosing where appropriate — as essential for sustaining the initial antidepressant response. Ask explicitly: what happens after the first treatment series? Is a licensed therapist part of the program? Is there a pathway for ongoing care if the treatment works?

What will this cost, in full? Ketamine treatment remains largely out-of-pocket for most patients in 2026, though some insurers now cover Spravato under specific diagnostic criteria. Telehealth oral ketamine programs vary widely in price. Ask for itemized costs upfront, understand what is and is not included, and be cautious of platforms that make pricing difficult to access before you have entered payment information.

Is the provider licensed to prescribe in your state? Telehealth prescribing rules for controlled substances vary by state and continue to shift in the post-pandemic regulatory environment. Before starting, confirm that the prescribing clinician holds an active license in your state and that the consultation satisfies the legal requirements for Schedule III prescriptions via telemedicine.

Explainers like the one Medical Daily published serve a genuine purpose: they help patients show up to clinical conversations better prepared and less intimidated by unfamiliar terminology. The evidence base supporting ketamine for TRD is strong and continuing to grow. What patients need now is not more convincing that ketamine is a legitimate option — it is enough information to evaluate the growing number of providers offering it.